Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.
Saved in:
| Title: | Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO. |
|---|---|
| Authors: | Ciracì, P.1,2 (AUTHOR), Germani, M.M.1,2 (AUTHOR), Pietrantonio, F.3 (AUTHOR), Manca, P.3 (AUTHOR), Lonardi, S.4 (AUTHOR), Busico, A.5 (AUTHOR), Bergamo, F.4 (AUTHOR), Burgio, V.6 (AUTHOR), Mannavola, F.7 (AUTHOR), Di Donato, S.8 (AUTHOR), Fenocchio, E.9 (AUTHOR), Palermo, F.3 (AUTHOR), Capone, I.5 (AUTHOR), De Grandis, M.C.4 (AUTHOR), Pella, N.10 (AUTHOR), Scartozzi, M.11 (AUTHOR), Antonuzzo, L.12 (AUTHOR), Passardi, A.13 (AUTHOR), Claravezza, M.14 (AUTHOR), Salvatore, L.15,16 (AUTHOR) |
| Source: | Annals of Oncology. Jan2026, Vol. 37 Issue 1, p79-91. 13p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.10.002 |
